Base Pair Biotechnologies, Inc.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Industries
Nr. of Employees
small (1-50)
Base Pair Biotechnologies, Inc.
8619 Broadway Street, Suite 100, Pearland, TX 77584 USA
Patents
Methods and materials for discovery of functional ligands to molecular complexes
US-12338434-B1
View Details
Methods and materials for discovery of functional ligands to molecular complexes
US-12338434-B1
View DetailsProducts
Catalog aptamers and reagents
Chemically synthesized oligonucleotide aptamers specific for a broad range of validated targets, available for research and diagnostic use.
DNA aptamers inhibiting vitamin C oxidation
DNA aptamers identified and validated to inhibit the oxidation of vitamin C, offering stabilization for use in food, beverages, and nutraceutical formulations.
Catalog aptamers and reagents
Chemically synthesized oligonucleotide aptamers specific for a broad range of validated targets, available for research and diagnostic use.
DNA aptamers inhibiting vitamin C oxidation
DNA aptamers identified and validated to inhibit the oxidation of vitamin C, offering stabilization for use in food, beverages, and nutraceutical formulations.
Services
Consultative and collaborative discovery of single- or multiplex aptamers tailored to user-defined targets through iterative SELEX and optimization.
Development and optimization of aptamer-based assays for diagnostics, detection, and biosensor applications, including lateral flow, ELASA, and other plate-based formats.
Analysis of aptamer selection data using next-generation sequencing and clustering and alignment algorithms to identify high-affinity candidates.
Enhancement of aptamer function via truncation, base substitution, and conjugation with chemical groups for improved stability, solubility, detection, or target affinity.
Measurement of aptamer-target binding kinetics using techniques such as biolayer interferometry and microscale thermophoresis, as well as validation in customer-specified functional assays.
Consultative and collaborative discovery of single- or multiplex aptamers tailored to user-defined targets through iterative SELEX and optimization.
Development and optimization of aptamer-based assays for diagnostics, detection, and biosensor applications, including lateral flow, ELASA, and other plate-based formats.
Analysis of aptamer selection data using next-generation sequencing and clustering and alignment algorithms to identify high-affinity candidates.
Enhancement of aptamer function via truncation, base substitution, and conjugation with chemical groups for improved stability, solubility, detection, or target affinity.
Measurement of aptamer-target binding kinetics using techniques such as biolayer interferometry and microscale thermophoresis, as well as validation in customer-specified functional assays.
Expertise Areas
- Aptamer discovery and selection
- Multiplex target binding
- Small molecule and toxin detection
- Molecular diagnostics development
Key Technologies
- SELEX (Systematic Evolution of Ligands by Exponential Enrichment)
- Multiplex SELEX
- Next-generation sequencing
- Microscale thermophoresis
News & Updates
Selected as a semi-finalist in the XPRIZE Rapid Covid Testing competition for development of a novel electrochemical sensor for rapid saliva testing utilizing proprietary aptamers.
Announcement of the opening of a new 5,000+ sq. ft. facility in Pearland, TX, expanding laboratory and office space.
Completion of a $3.2 million Series A-3 financing round and the opening of a new laboratory and office facility.
Awarded a NIH SBIR contract for development and validation of non-mouse reagents for preclinical development of novel therapeutics, focusing on canine models for oncology research.
Discovery of aptamers capable of inhibiting vitamin C oxidation, with implications for food, beverages, supplements, and cosmetics.
Coverage of aptamers as alternatives to immunization and patented custom aptamer development.
Selected as a semi-finalist in the XPRIZE Rapid Covid Testing competition for development of a novel electrochemical sensor for rapid saliva testing utilizing proprietary aptamers.
Announcement of the opening of a new 5,000+ sq. ft. facility in Pearland, TX, expanding laboratory and office space.
Completion of a $3.2 million Series A-3 financing round and the opening of a new laboratory and office facility.
Awarded a NIH SBIR contract for development and validation of non-mouse reagents for preclinical development of novel therapeutics, focusing on canine models for oncology research.
Discovery of aptamers capable of inhibiting vitamin C oxidation, with implications for food, beverages, supplements, and cosmetics.
Coverage of aptamers as alternatives to immunization and patented custom aptamer development.